Why is Korean sunscreen different from the sunscreen you can buy here?

Because the United States regulates sunscreen as a drug and Korea regulates it as a cosmetic, and that one difference decides which UV filters a formulator is allowed to use. The US permits seventeen. Korea permits around thirty-two. A Korean sunscreen sold through an American retailer has usually been rebuilt with different ingredients to get here.

The part almost every article about this gets wrong

You will read that the FDA has not approved a new sunscreen filter since 1999.

That was true until June 2026. It is not true now.

On June 9, 2026 the FDA issued a final order adding bemotrizinol, permitted up to 6 percent, effective that August. The agency's own headline called it the first expansion of sunscreen options in twenty years.

That is the good news. Here is the rest of it.

The application for bemotrizinol was first filed in 2005. A 2017 report from the Government Accountability Office found it still pending, along with seven others filed between 2002 and 2009, every one of them waiting on safety and effectiveness data the FDA had asked for. It was finally cleared twenty-one years after that first filing, and not on the original application. It came through a second request from a different company, DSM.

And the company that did the work holds an exclusive. Under the statute DSM has the sole right to market products containing bemotrizinol for eighteen months, running to February 2028, extending to anyone it licenses. Licensing is the route in, and as of this autumn most brands have not taken it.

Why a drug and not a cosmetic

In the US, sunscreen is an over-the-counter drug. That is not a marketing distinction. It is a legal category, and everything follows from it.

A compliant sunscreen has to be made in a registered drug facility. That facility pays an annual FDA fee, $47,891 in the 2027 fiscal year. The product carries a Drug Facts panel. It follows drug manufacturing rules. And its active ingredients have to come from a fixed list in something called OTC Monograph M020.

In Korea, sunscreen is a 기능성화장품, a functional cosmetic. A cosmetic with one extra gate: every sunscreen has to be reviewed by or reported to the Ministry of Food and Drug Safety before it can be sold, with documentation supporting its SPF and UVA numbers.

Notice what that means, because it is the opposite of the lazy version of this story. Korea reviews products, one at a time. The US reviews the formula rather than the product, and a sunscreen that stays inside the monograph needs no approval before it goes on sale. What Korea does not do is treat a UV filter as a drug active. That is why its list can be amended by notice and the American one sat still for twenty-seven years.

The list, and how fast it just moved

Sixteen filters, from 1999 until the middle of this year. Then two changes in four months.

Bemotrizinol added, effective August 2026. Then on September 11, 2026 the FDA ordered PABA and trolamine salicylate off the list entirely, finding that their risks outweigh their benefits. That removal is set to take effect a year later, in September 2027, unless it is disputed.

Sixteen, then seventeen, then fifteen.

Filters permitted in Korea and Europe but still not here include methylene bis-benzotriazolyl tetramethylbutylphenol, diethylamino hydroxybenzoyl hexyl benzoate, ethylhexyl triazone and drometrizole trisiloxane. If you have ever turned over a Korean sunscreen and not recognised a single active ingredient, that is why.

One correction worth making, because it circulates constantly. Ecamsule, sold as Mexoryl SX, is not banned in the US. It is simply not on the monograph. It arrived here in 2006 inside an L'Oréal product approved through a full drug application, and it is still only in a handful of products from that one company. There are two doors into the American market, and almost nobody uses the second one.

Using approved filters is still not enough

This is the part that surprised me most.

In November 2024 the FDA sent a warning letter to a French company over a sunscreen whose four active ingredients were each individually permitted. Octocrylene, oxybenzone, avobenzone, ensulizole. All four on the list.

The FDA called it an unapproved new drug anyway. Its words were that "this combination of active ingredients is not permitted under M020.20." The monograph specifies which filters may be used together, not only which may be used at all.

So the US does not regulate an ingredient list. It regulates a formulation. A Korean formulator cannot reach a compliant American product by swapping a few ingredients and ticking them off.

What actually happens when a Korean sunscreen shows up on an American site

If it reaches you through a retailer that treats it as a drug, meaning a brand's own US store or a US beauty retailer, it has almost certainly been reformulated. Beauty of Joseon, for instance, sells a separate American sunscreen, Day Dew, and its Drug Facts panel lists avobenzone, homosalate, octisalate and octocrylene. All monograph filters. That is not the formula sold in Korea.

If it reaches you as the Korean product in Korean packaging, it has not been reformulated, and it is not legally marketed in the United States. A sunscreen whose filters are not permitted here is an unapproved new drug, and the FDA has written to companies saying exactly that. In August 2025 it wrote to a Swedish brand over a product built on diethylamino hydroxybenzoyl hexyl benzoate, bemotrizinol and ethylhexyl triazone, none of them permitted at the time, and separately over the fact that no order authorises sunscreen in a mousse format at all.

Those are the same filter families a Korean sunscreen uses, though I should be straight with you: the enforcement cases I can point to are European. I could not find one naming a Korean company.

The one difference you can see on a label

American sunscreen either says "Broad Spectrum" or it does not. Pass or fail, awarded if the product reaches a mean critical wavelength of 370 nanometres.

Korean sunscreen grades UVA protection from PA+ to PA++++, tied to a measured protection factor.

So two American sunscreens can both say "Broad Spectrum" while one clears that threshold comfortably and the other only just, and the label is not permitted to tell you which. That is not an opinion about whose sunscreen is better. It is a fact about what each label is allowed to say.

On whether the filters themselves perform better, the research genuinely disagrees. A 2025 review in Photodermatology, Photoimmunology and Photomedicine argues that the Korean and European filters give superior UVA and UVB protection. A 2023 review in the Journal of the American Academy of Dermatology, comparing the US with the European Union rather than Korea, found that both systems provide adequate photoprotection when products are used as directed, and that the American filters have considerably more sensitisation safety data behind them. I am not going to pick a side I am not qualified to pick.

Why I do not sell sunscreen

ViaJiin carries no SPF, and this is the reason.

Every other product in a ViaJiin kit is a cosmetic in both countries, so I can source it in Korea and ship it to you as what it is. Sunscreen is not. Selling it would mean becoming a drug business: registered facility, annual fee, Drug Facts panel, a formulation built to the monograph. That is a different company from the one I am building.

The absence is a decision. It is not a gap in the routine.

Please do wear sunscreen every day, and buy it here, as a US-labelled over-the-counter drug. I do not sell it, I do not source it, and I am not suggesting you import the Korean version. The rules exist, whatever anyone thinks of the pace they move at.

Every number above is current as of September 2026, in a category that has changed twice this year.

If you want the wider version of this question, covering cosmetics rather than sunscreen, I wrote about whether Korean skincare is FDA approved, and the honest answer is that no cosmetic is, anywhere.